| Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease CK Negi, P Babica, L Bajard, J Bienertova-Vasku, G Tarantino Metabolism 126, 154925, 2022 | 162 | 2022 |
| Application of AOPs to assist regulatory assessment of chemical risks–Case studies, needs and recommendations L Bajard, O Adamovsky, K Audouze, K Baken, R Barouki, JB Beltman, ... Environmental Research 217, 114650, 2023 | 37 | 2023 |
| An adverse outcome pathway based in vitro characterization of novel flame retardants-induced hepatic steatosis CK Negi, L Bajard, J Kohoutek, L Blaha Environmental Pollution 289, 117855, 2021 | 36 | 2021 |
| Endocrine disrupting potential of replacement flame retardants–review of current knowledge for nuclear receptors associated with reproductive outcomes L Bajard, CK Negi, V Mustieles, L Melymuk, S Jomini, ... Environment International 153, 106550, 2021 | 33 | 2021 |
| Nrf2, a novel molecular target to reduce type 1 diabetes associated secondary complications: The basic considerations CK Negi, G Jena European Journal of Pharmacology 843, 12-26, 2019 | 27 | 2019 |
| Replacement flame-retardant 2-ethylhexyldiphenyl phosphate (EHDPP) disrupts hepatic lipidome: evidence from human 3D hepatospheroid cell culture CK Negi, D Gadara, J Kohoutek, L Bajard, Z Spacil, L Blaha Environmental Science & Technology 57 (5), 2006-2018, 2023 | 6 | 2023 |
| Flame retardants-mediated interferon signaling in the pathogenesis of nonalcoholic fatty liver disease CK Negi, S Khan, H Dirven, L Bajard, L Bláha International journal of molecular sciences 22 (8), 4282, 2021 | 6 | 2021 |
| Anti-androgenic activity of novel flame retardants in mixtures: Newly identified contribution from tris (2, 3-dibromopropyl) isocyanurate (TDBP-TAZTO) L Bajard, H Vespalcová, CK Negi, J Kohoutek, L Bláha, I Sovadinová Chemosphere 341, 140004, 2023 | | 2023 |
Lola BajardVerified email at mpi-cbg.de
